President Trump misunderstands what government drug price negotiations entail

by is licensed under
President Trump recently pledged to let federal officials negotiate the prices of drugs covered under Medicare. He claims this will save taxpayers billions of dollars.

Nobody doubts that Trump and his team are shrewd negotiators. But the sorts of "negotiations" that Trump refers to have nothing in common with haggling over a real estate deal. Instead, the action that Trump has proposed — repealing the non-interference clause, originally drafted by Democratic Senators Ted Kennedy and Tom Daschle — would result in Medicare drug prices going up and patient choice going down.

This clause has been the key to Medicare's success. Between 2004 and 2013, the Medicare "Part D" prescription drug benefit program cost an extraordinary 45 percent less than initial estimates. Premiums for the program also are roughly half of the government's original projections.

These unprecedented results are largely due to Part D's market-based structure. Beneficiaries are free to choose from a slate of private drug coverage plans, forcing insurers to compete to offer the best options to American seniors. This year, seniors can choose from among 746 plans nationwide, with an average monthly premium of around $35.

 
Article Photo Credit: by is licensed under
Sign Up for Our Email Newsletter

RECENT NEWS

New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases

New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases

Authors argue that rare disease innovation requires learning more from fewer patients—not enrolling more patients...  Read more

Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs

Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs

Texas has an opportunity to lead rather than react. Better measurement would strengthen public confidence without diminis...  Read more

PROTECTING THE U.S. PHARMACEUTICAL SUPPLY CHAIN: A PATH FORWARD

PROTECTING THE U.S. PHARMACEUTICAL SUPPLY CHAIN: A PATH FORWARD

How proactive FDA policies can help strengthen the American pharmaceutical supply chain of essential medicines, create jo...  Read more

DRUGWONKS BLOG